dihexa safety concerns hgf c-met cancer risk Frontiers Dihexa (PNB-0408) | c-Met/HGFR Activator
Dihexa (PNB 0408) c Met HGFR Activator MedChemExpress Targeting cancer associated fibroblast activated HGF c MET pathway inhibits extrahepatic cholangiocarcinoma progression and restores gemcitabine therapeutic sensitivity ScienceDirect Targeting the HGF c MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis British Journal of Cancer Developing c MET pathway inhibitors for cancer therapy: progress and challenges: Trends in Molecular Medicine
Pay in 4 interest-free payments of $6.96 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4



